nonacus-developer

What is targeted next generation sequencing?

By nonacus-developer / March 31, 2023 / Comments Off on What is targeted next generation sequencing?

March 31, 2023 And why is it used for liquid biopsy samples? Targeted next generation sequencing (NGS) focuses sequencing efforts on specific subsets of the genome. By focusing only on regions of interest (ROIs) such as certain genes, hotspots or coding regions, it is possible to achieve greater coverage and improved sensitivity of variant calling.…

Read More

The importance of using an optimized pre-analytical workflow for liquid biopsy analysis

By nonacus-developer / February 14, 2023 / Comments Off on The importance of using an optimized pre-analytical workflow for liquid biopsy analysis

February 14, 2023 Do you use cell-free DNA as a biomarker for clinical diagnostics or medical research? Find out how using a workflow specifically designed for liquid biopsies can help improve the quantity and quality of your cell-free DNA samples. Liquid biopsies are increasingly used to guide clinical decisions in the cancer healthcare field. Although…

Read More

COVID-19, Flu and RSV – What makes them different?

By nonacus-developer / September 28, 2022 / Comments Off on COVID-19, Flu and RSV – What makes them different?

SEPTEMBER 28, 2022 Despite causing similar symptoms, there are key differences between COVID-19, flu and RSV such as the size and structure of the viral genomes as well as the virion proteins. These differences allow us to design tests to distinguish between these viral infections and develop treatments and vaccines specific to each. Respiratory infections…

Read More

Liquid biopsy: The future of minimal residual disease detection?

By nonacus-developer / March 24, 2022 / Comments Off on Liquid biopsy: The future of minimal residual disease detection?

MARCH 16, 2022 Detection of Minimal Residual Disease Minimal residual disease (MRD) is defined as a very small number of cancer cells that remain in the body during or after treatment1. This may be locally at the site of surgery, distant at metastatic sites or at unknown micrometastatic deposits. The assessment of post-treatment minimal residual…

Read More

Detecting multiple respiratory viruses with a single qRT-PCR assay

By nonacus-developer / March 16, 2022 / Comments Off on Detecting multiple respiratory viruses with a single qRT-PCR assay

MARCH 11, 2022 Why a negative COVID test result doesn’t always give the full picture of viral infection. As some of the symptoms of COVID-19 overlap with influenza and respiratory syncytial virus (RSV), a negative COVID test result doesn’t always give the full picture of infection. Testing for multiple respiratory viruses in one simple qRT-PCR…

Read More

Unique molecular identifiers: the key to unmasking real low frequency variants

By nonacus-developer / January 28, 2022 / Comments Off on Unique molecular identifiers: the key to unmasking real low frequency variants

January 28, 2022 How molecular barcodes help remove the PCR and sequencing errors that can mask important low-frequency variations in the analysis of cell-free DNA. Next Generation Sequencing (NGS) technologies are powerful tools that have accelerated the rate of life science research for the last decade. This is especially true in the areas of oncology…

Read More

Tumour Mutational Burden (TMB) and Microsatellite Instability (MSI) as markers for immunotherapy response

By nonacus-developer / December 22, 2021 / Comments Off on Tumour Mutational Burden (TMB) and Microsatellite Instability (MSI) as markers for immunotherapy response

Published December 22, 2021 | Reviewed by Victoria Simms on April, 22, 2024 The promise of Immune-checkpoint inhibitor therapies Immune-checkpoint inhibitor (ICI) therapies have heralded promise of a superior drug response and significantly increased survival for a small proportion of cancer patients across a range of cancers. Their success lies in the inhibition of biological mechanisms that prevent immune cells from attacking other cells. The challenge for immuno-oncology is to identify…

Read More

Liquid biopsies: epigenetic clues for early cancer detection

By nonacus-developer / November 17, 2021 / Comments Off on Liquid biopsies: epigenetic clues for early cancer detection

November 17, 2021 Current screening limitations Cancer is a leading cause of morbidity and mortality globally. Despite early diagnosis and treatment being one of the most effective methods to improve outcomes for cancer patients, early detection remains challenging. Screening methods are available for some tumour types, such as the smear test for cervical cancer and mammography for breast cancer1,2. However, these early…

Read More

Nonacus Cell3™ Target technology assists with DNA methylation sequencing

By nonacus-developer / November 11, 2021 / Comments Off on Nonacus Cell3™ Target technology assists with DNA methylation sequencing

November 11, 2021 Researchers at The Centre For Genomic and Experimental Medicine, University of Edinburgh, have used Nonacus Cell3™ Target technology to undertake targeted DNA methylation sequencing with the aim of finding DNA methylation specific breast cancer markers. This work is funded by Cancer Research UK. Nonacus spoke to Dr. Martyna Adamowicz from the Centre for…

Read More

Tracking the evolution of SARS CoV-2 using Whole Genome Sequencing (WGS)

By nonacus-developer / November 3, 2021 / Comments Off on Tracking the evolution of SARS CoV-2 using Whole Genome Sequencing (WGS)

November 3, 2021 Tracking SARS-CoV-2 using Whole Genome Sequencing Why monitoring the evolution of the virus is crucial to public health Viral genome sequencing: the background story Rapid whole viral genome sequencing, decoding a pathogen’s entire genome, is essential to public health organisations and epidemiologists for tracking and surveillance of disease outbreaks. Genomic epidemiologists around…

Read More